NLRP3 and myeloid sarcoma: Accumulating evidence showed that NLRP3 inflammasome is activated during the pathogenesis of MS/EAE, and its downstream products, including IL‐1β and IL‐18, can compromise the blood‐brain barrier, induce neural toxicity, stimulate autoimmune T cells and then deteriorate MS/EAE.44, 45, 64, 65